FDA Approval: Blinatumomab

被引：280

作者：

Przepiorka, Donna ^{[1
]}

Ko, Chia-Wen ^{[1
]}

Deisseroth, Albert ^{[1
]}

Yancey, Carolyn L. ^{[1
]}

Candau-Chacon, Reyes ^{[1
]}

Chiu, Haw-Jyh ^{[1
]}

Gehrke, Brenda J. ^{[1
]}

Gomez-Broughton, Candace ^{[1
]}

Kane, Robert C. ^{[1
]}

Kirshner, Susan ^{[1
]}

Mehrotra, Nitin ^{[1
]}

Ricks, Tiffany K. ^{[1
]}

Schmiel, Deborah ^{[1
]}

Song, Pengfei ^{[1
]}

Zhao, Ping ^{[1
]}

Zhou, Qing ^{[1
]}

Farrell, Ann T. ^{[1
]}

Pazdur, Richard ^{[1
]}

机构：

[1] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 18期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; SALVAGE THERAPY; CHEMOTHERAPY; ADULTS;

D O I：

10.1158/1078-0432.CCR-15-0612

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a recombinant murine protein that acts as a bispecific CD19-directed CD3 T-cell engager. The basis for the approval was a single-arm trial with 185 evaluable adults with R/R ALL. The complete remission (CR) rate was 32%[95% confidence interval (CI), 26%-40%], and the median duration of response was 6.7 months. A minimal residual disease response was achieved by 31% (95% CI, 25%-39%) of all patients. Cytokine release syndrome and neurologic events were serious toxicities that occurred. Other common (>20%) adverse reactions were pyrexia, headache, edema, febrile neutropenia, nausea, tremor, and rash. Neutropenia, thrombocytopenia, and elevated transaminases were the most common (>10%) laboratory abnormalities related to blinatumomab. A randomized trial is required in order to confirm clinical benefit. (C)2015 AACR.

引用

页码：4035 / 4039

页数：5

共 19 条

[1]

[Anonymous], 2014, FULL PRESCR INF CLOL

[2]

[Anonymous], 2012, FULL PRESCR INF MARQ

[3]

[Anonymous], DRUGS FDA

[4] End points to establish the efficacy of new agents in the treatment of acute leukemia [J].

Appelbaum, Frederick R. ;

Rosenblum, Daniel ;

Arceci, Robert J. ;

Carroll, William L. ;

Breitfeld, Philip P. ;

Forman, Stephen J. ;

Larson, Richard A. ;

Lee, Stephanie J. ;

Murphy, Sharon B. ;

O'Brien, Susan ;

Radich, Jerald ;

Scher, Nancy S. ;

Smith, Franklin O. ;

Stone, Richard M. ;

Tallman, Martin S. .

BLOOD, 2007, 109 (05) :1810-1816

[5]

Bioemena E, 1990, TRANSPLANTATION, V50, P330

[6] INVIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION - SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS [J].

CHATENOUD, L ;

FERRAN, C ;

LEGENDRE, C ;

THOUARD, I ;

MERITE, S ;

REUTER, A ;

GEVAERT, Y ;

KREIS, H ;

FRANCHIMONT, P ;

BACH, JF .

TRANSPLANTATION, 1990, 49 (04) :697-702

[7]

DILLMAN RO, 1986, J BIOL RESP MODIF, V5, P73

[8] Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy [J].

Faderl, Stefan ;

Thomas, Deborah Ann ;

O'Brien, Susan ;

Ravandi, Farhad ;

Garcia-Manero, Guillermo ;

Borthakur, Gautam ;

Ferrajoli, Alessandra ;

Verstovsek, Srdan ;

Ayoubi, Mohamed ;

Rytting, Michael ;

Feliu, Jennie ;

Kantarjian, Hagop M. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01) :54-59

[9] Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation [J].

Goekbuget, Nicola ;

Stanze, Daniel ;

Beck, Joachim ;

Diedrich, Helmut ;

Horst, Heinz-August ;

Huettmann, Andreas ;

Kobbe, Guido ;

Kreuzer, Karl-Anton ;

Leimer, Lothar ;

Reichle, Albrecht ;

Schaich, Markus ;

Schwartz, Stefan ;

Serve, Hubert ;

Starck, Michael ;

Stelljes, Matthias ;

Stuhlmann, Reingard ;

Viardot, Andreas ;

Wendelin, Knut ;

Freund, Mathias ;

Hoelzer, Dieter .

BLOOD, 2012, 120 (10) :2032-2041

[10] Defining the Course and Prognosis of Adults With Acute Lymphocytic Leukemia in First Salvage After Induction Failure or Short First Remission Duration [J].

Kantarjian, Hagop M. ;

Thomas, Deborah ;

Ravandi, Farhad ;

Faderl, Stefan ;

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Pierce, Sherry ;

Shan, Jianquin ;

Cortes, Jorge ;

Brien, Susan O. .

CANCER, 2010, 116 (24) :5568-5574

← 1 2 →